Association Between Lipoprotein(a) Testing, Lipid‐Lowering Therapy Intensification, and Low‐Density Lipoprotein Cholesterol Goal Attainment: Findings From the Veterans Affairs Health System
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.046519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Shyon Parsa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Stanford University Hospital Stanford CA. Hauptthemen laut MEDLINE: Lipoprotein(a), Cholesterol, LDL, Hypolipidemic Agents, Dyslipidemias. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Lipoprotein(a) (Lp[a]) can refine atherosclerotic cardiovascular disease risk assessment and guide lipid‐lowering therapy intensification (LLTI). However, the association between Lp(a) testing and LLTI across large health systems is not well characterized.
Methods
Using Veterans Affairs electronic health record data, we conducted a retrospective cohort study of veterans undergoing lipid testing from January 1, 2017, to June 30, 2024. We first compared a 1:1 propensity‐matched cohort with concurrent low‐density lipoprotein cholesterol (LDL‐C) and Lp(a) testing with those with LDL‐C testing alone. We then compared veterans with elevated versus nonelevated Lp(a) (>50 versus
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine Stanford University Hospital Stanford CA.
- Department of Internal Medicine Jacobi Hospital/Albert Einstein College of Medicine New York NY.
- Division of Cardiovascular Medicine and Cardiovascular Institute Stanford University School of Medicine Stanford CA.
- Veterans Affairs Palo Alto Health Care System Palo Alto CA.
- Division of Cardiovascular Medicine University of California San Francisco San Francisco CA.
- Novartis Pharmaceuticals Corporation East Hanover NJ.
ORCID-Profile: Shyon Parsa, Priyansh Shah, Ramzi Dudum, Natasha Din, David Maron, Paul Heidenreich, Jonathan H Ward, Alexander T Sandhu, Fatima Rodriguez
Zitieren
APA
Parsa, S., Shah, P., Furst, A., Dudum, R., Din, N., Maron, D., Heidenreich, P., Ward, J. H., Lozama, A., Sandhu, A. T., & Rodriguez, F. (2026). Association Between Lipoprotein(a) Testing, Lipid‐Lowering Therapy Intensification, and Low‐Density Lipoprotein Cholesterol Goal Attainment: Findings From the Veterans Affairs Health System. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.046519
Vancouver
Parsa S, Shah P, Furst A, Dudum R, Din N, Maron D, et al. Association Between Lipoprotein(a) Testing, Lipid‐Lowering Therapy Intensification, and Low‐Density Lipoprotein Cholesterol Goal Attainment: Findings From the Veterans Affairs Health System. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.046519
BibTeX
@article{Parsa2026,
author = {Parsa, Shyon and Shah, Priyansh and Furst, Adam and Dudum, Ramzi and Din, Natasha and Maron, David and Heidenreich, Paul and Ward, Jonathan H and Lozama, Anthony and Sandhu, Alexander T and Rodriguez, Fatima},
title = {Association Between Lipoprotein(a) Testing, Lipid‐Lowering Therapy Intensification, and Low‐Density Lipoprotein Cholesterol Goal Attainment: Findings From the Veterans Affairs Health System},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.046519}
}
EUVIMED